Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Cytosorbents Corporation

Market Cap 25.07M 21.61M 19.88M 18.65M 35.04M 2.37B 35.39M 235M 91.82M 1.16B 94.07M 92.08M 4.01B P/E Ratio 2026 *
-2.16x
P/E Ratio 2027 * 13.3x
Enterprise Value 25.07M 21.61M 19.88M 18.65M 35.04M 2.37B 35.39M 235M 91.82M 1.16B 94.07M 92.08M 4.01B EV / Sales 2026 *
0.66x
EV / Sales 2027 * 0.53x
Free-Float
85.15%
Yield 2026 *
-
Yield 2027 * -
1 day+12.43%
1 week+8.52%
Current month-8.43%
1 month-9.67%
3 months-30.86%
6 months-28.21%
Current year-29.68%
1 week 0.37
Extreme 0.3695
0.47
1 month 0.37
Extreme 0.3695
0.53
Current year 0.37
Extreme 0.3695
0.84
1 year 0.37
Extreme 0.3695
1.39
3 years 0.37
Extreme 0.3695
4.29
5 years 0.37
Extreme 0.3695
9.8
10 years 0.37
Extreme 0.3695
14.95
Manager TitleAgeSince
Chief Executive Officer 55 23/07/2008
Director of Finance/CFO 62 13/08/2024
President 68 27/04/2020
Director TitleAgeSince
Chairman 62 -
Director/Board Member 55 31/12/2008
Director/Board Member 77 24/07/2011
Date Insider Type Main position Quantity % Market Cap.
11-17Free

Chief Executive Officer

100,000 0.1593%
07/08/25Free

Chief Executive Officer

242,000 0.3865%
07/08/25Other

Chairman

44,000 0.0703%
Change 5-day change 1-year change 3-year change Capi.($)
+8.05%+8.52%-63.16%-87.41% 25.07M
+1.03%+0.87%+16.94%-11.47% 174B
+1.34%-0.49%-19.75%+26.89% 146B
+0.56%-1.32%-9.95%-25.63% 127B
-0.32%-3.98%-53.93%-13.38% 69.72B
+1.37%+0.50%+15.32%-5.49% 49.01B
+0.95%+0.34%-23.42%-33.71% 44.74B
+0.58%-1.58%+9.72%+7.72% 36.67B
+0.63%-1.54%+2.86%+33.45% 34.91B
-0.64%+0.14%-11.12%-18.13% 29.65B
Average +2.14%-2.95%-13.65%-12.72% 71.22B
Weighted average by Cap. +0.97%-1.87%-7.19%-4.43%

Financials

2026 *2027 *
Net sales 38.26M 32.98M 30.35M 28.47M 53.49M 3.62B 54.02M 359M 140M 1.77B 144M 141M 6.13B 47.12M 40.62M 37.38M 35.07M 65.87M 4.45B 66.53M 442M 173M 2.18B 177M 173M 7.55B
Net income -11.74M -10.12M -9.31M -8.74M -16.41M -1.11B -16.58M -110M -43.01M -543M -44.06M -43.13M -1.88B 2.37M 2.05M 1.88M 1.77M 3.32M 224M 3.35M 22.25M 8.69M 110M 8.91M 8.72M 380M
Net Debt - -
Logo Cytosorbents Corporation
CytoSorbents Corporation is engaged in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery through blood purification. The Company’s blood purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its lead product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses that can lead to massive inflammation, organ failure and patient death. Its products also include ECOS-300CY, VetResQ, DrugSorb-ATR, and PuriFi. DrugSorb-ATR is an investigational device that uses equivalent polymer technology to CytoSorb to address a large unmet need for blood thinner reversal in cardiothoracic surgery. ECOS-300CY is used to reduce cytokines and other inflammatory mediators when used in an ex vivo organ perfusion system.
Employees
129
Date Price Change Volume
15/06/26 0.4320 $ +8.05% 228,350
12/06/26 0.3998 $ +3.01% 440,468
11/06/26 0.3881 $ -5.57% 441,186
10/06/26 0.4110 $ -2.72% 76,842
09/06/26 0.4225 $ +2.00% 94,802
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
0.3998USD
Average target price
2.875USD
Spread / Average Target
+619.11%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CTSO Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!